Disintegrin and metalloproteinase domain-containing protein 9
Synonyms
Disintegrin and metalloproteinase domain-containing protein 9 (EC:3.4.24.-)
Cellular disintegrin-related protein,Meltrin-gamma,Metalloprotease,disintegrin,cysteine-rich protein 9,Myeloma cell metalloproteinase,ADAM9,KIAA0021, MCMP, MDC9, MLTNG
Drug Development Progress
Drugs in Clinical Trials3
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Meltrin-gamma,ADAM Metallopeptidase Domain 9 (Meltrin Gamma),Cellular disintegrin-related protein,ADAM 9,Metalloprotease/disintegrin/cysteine-rich protein 9,Mltng,MDC9,KIAA0021,Meltrin Gamma,CORD9,A Disintegrin And Metalloproteinase Domain 9 (Meltrin Gamma),ADAM Metallopeptidase Domain 9,Cone Rod Dystrophy 9,MCMP,Myeloma cell metalloproteinase
Background
ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin domain for adhesion and the metalloprotease domain for ectodomain shedding of a wide variety of cell surface proteins. ADAM9 influences the developmental process, inflammation, and degenerative diseases.Recently, increasing evidence has shown that ADAM9 plays an important role in tumor biology. Overexpression of ADAM9 has been found in several cancer types and is correlated with tumoraggressiveness and poor prognosis. In addition, through either proteolytic or non-proteolytic pathways, ADAM9 promotes tumor progression, therapeutic resistance, and metastasis of cancers.Therefore, comprehensively understanding the mechanism of ADAM9 is crucial for the development of therapeutic anti-cancer strategies. In this review, we summarize the current understanding of ADAM9 in biological function, pathophysiological diseases, and various cancers. Recent advances in therapeutic strategies using ADAM9-related pathways are presented as well.
ADAM9 Product List
No Data
You Have Viewed 0 Of 0 Results
1
No Data
No Data
Can’t find what you need?
Submit your requirements and our technical team will help.
BCMA binds to its ligands, APRIL and BAFF, activating downstream signaling pathways such as NF-κB that promote plasma cell survival, proliferation, and immune evasion. Because multiple myeloma cells rely on BCMA signaling for growth and survival, targeting BCMA has become one of the most effective therapeutic strategies for treating MM.
Q
What is BCMA, and why is it an ideal therapeutic target for multiple myeloma (MM)?
B-cell Maturation Antigen (BCMA) is a member of the tumor necrosis factor receptor (TNFR) superfamily. It is primarily expressed on mature B cells and plasma cells, with limited expression in normal tissues, while remaining highly expressed on the majority of multiple myeloma (MM) cells. Its restricted tissue distribution and stable tumor expression make BCMA one of the most attractive targets for the development of CAR-T cell therapies, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs).
Q
What critical biophysical quality attributes make ACROBiosystems' anti-idiotypic antibodies highly reliable across multi-year clinical campaigns?
Multi-year clinical trials require reagents with unwavering batch consistency and minimal risk of assay drift. ACROBiosystems’ anti-idiotypic antibody portfolio features:
Picomolar Affinity (KD): Characterized via Surface Plasmon Resonance (SPR), reaching picomolar binding strength (e.g., clone ADB-Y19 binds Adalimumab with an affinity constant of 1.36 pM).
SEC-MALS Verification: Select clones undergo Size-Exclusion Chromatography coupled with Multi-Angle Light Scattering (SEC-MALS) to confirm purity and a defined monomeric molecular weight.
High Thermal & Freeze-Thaw Stability: Validated through accelerated 37°C stress tests and repeated freeze-thaw cycles without activity loss.
Q
What critical biophysical quality attributes make ACROBiosystems' anti-idiotypic antibodies highly reliable across multi-year clinical campaigns?
Multi-year clinical trials require reagents with unwavering batch consistency and minimal risk of assay drift. ACROBiosystems’ anti-idiotypic antibody portfolio features:
Picomolar Affinity (KD): Characterized via Surface Plasmon Resonance (SPR), reaching picomolar binding strength (e.g., clone ADB-Y19 binds Adalimumab with an affinity constant of 1.36 pM).
SEC-MALS Verification: Select clones undergo Size-Exclusion Chromatography coupled with Multi-Angle Light Scattering (SEC-MALS) to confirm purity and a defined monomeric molecular weight.
High Thermal & Freeze-Thaw Stability: Validated through accelerated 37°C stress tests and repeated freeze-thaw cycles without activity loss.
Q
How do cell-based reporter bioassays and stable overexpression cell lines complement cell-free assays during anti-PD-L1 antibody screening?
While recombinant proteins provide precise cell-free kinetic parameters (SPR/ELISA), cell-based models confirm functional antibody activity in native membrane geometry. ACROBiosystems provides PD-L1 Overexpression Stable Cell Lines and Cell-Based Reporter Bioassays:
Overexpression Cell Lines: Display full-length human PD-L1 with authentic post-translational modifications, supporting flow cytometry (FACS) binding and competition studies.
Reporter Bioassays: Quantify the functional blockade of the PD-1/PD-L1 signaling axis by measuring NFAT or NF-κB promoter-driven luciferase activity upon co-culture, providing reproducible bioactivity data for lot release and characterization.
Q
What research tools are available for PD-L1 studies?
PD-L1 research often requires different tools depending on the application. Recombinant proteins, assay kits, cell lines, and antibodies can be used across different research workflows. ACROBiosystems provides these PD-L1 research tools in multiple species and formats to support binding studies, inhibitor screening, assay development, and cell-based research.